Connect with us

Business

Former SBP governor Shamshad Akhtar dies at 71 | The Express Tribune

Published

on

Former SBP governor Shamshad Akhtar dies at 71 | The Express Tribune


She served as 14th SBP governor and later as caretaker finance minister before the 2018 and 2024 general elections

A file photo of former State Bank of Pakistan governor Dr Shamshad Akhtar during a news conference in Karachi on October 17, 2008. Photo: Reuters/ File

Shamshad Akhtar, the first and only woman to serve as governor of the State Bank of Pakistan and a two-time caretaker finance minister, passed away at the age of 71, the Ministry of Finance said on Saturday.

At the time of her death, Akhtar was serving as chairperson of the Pakistan Stock Exchange, marking a rare distinction of having led the country’s central bank, overseen fiscal management, and headed a key capital markets institution.

She served as 14th governor of the State Bank of Pakistan from 2006 to 2009 and later assumed the role of caretaker finance minister during the interim governments formed ahead of the 2018 and 2024 general elections.

Born in Hyderabad, Akhtar received her early education in Karachi and Islamabad and was known for her strong academic background. She graduated with a BA in Economics from the University of Punjab in 1974 and later earned an MSc in Economics from Quaid-e-Azam University, Islamabad. She went on to obtain an MA in Development Economics from the University of Sussex in 1977 and a PhD in Economics from the UK’s Paisley College of Technology in 1980.

Akhtar was also a Fulbright postdoctoral fellow and served as a visiting fellow at Harvard University’s Department of Economics in 1987.

President Asif Ali Zardari expressed profound grief over the passing of former State Bank of Pakistan governor Shamshad Akhtar, paying tribute to her lifelong commitment to public service and her role in strengthening economic governance and financial management in the country.

In a post shared on X by Presidential Spokesperson Murtaza Solangi, the president said he was deeply saddened by Akhtar’s death and acknowledged her contributions to the field of economics and public finance. He prayed for the elevation of the departed soul’s ranks and extended heartfelt condolences to the bereaved family.

Pakistan Stock Exchange also mourned the loss of its late Chairperson. “The Board and Management of Pakistan Stock Exchange express deep sorrow on the passing of Dr Shamshad Akhtar, Chairperson PSX. Dr Akhtar was a distinguished leader whose legacy and service will always be remembered, PSX wrote.

An economic stalwart

Pakistan’s economic and financial community is mourning the loss of Dr Shamshad Akhtar, who was widely regarded as one of the country’s most influential economic managers. Dr Akhtar played an active, hands-on role during Pakistan’s most difficult financial periods, contributing to policy responses to balance-of-payments pressures and participating in critical negotiations with the International Monetary Fund (IMF) to help stabilise the economy.

She broke new ground in 2006 when she became the first woman to head the State Bank of Pakistan, serving as its governor at a time when banking sector reforms and monetary tightening were central to economic management. Her tenure is remembered for strengthening financial regulation and enhancing the independence and credibility of the central bank.

Dr Akhtar later returned to public service as finance minister in caretaker governments formed in 2023, where she was entrusted with managing fragile economic conditions, engaging with international lenders, and ensuring continuity in fiscal and monetary policy during political transitions.

Beyond Pakistan, she built an exceptional global career, holding senior positions at leading international institutions. These included serving as Vice President of the World Bank for the Middle East and North Africa, Executive Secretary of the UN’s ESCAP, and senior leadership roles at the Asian Development Bank, where she oversaw development, governance, and financial programmes across Asia.

In addition to her public sector roles, Dr Akhtar also served in leadership positions within Pakistan’s capital markets, including her association with the Pakistan Stock Exchange (PSX), where she was Chairperson PSX Board and contributed to improving corporate governance, market transparency, and investor confidence.

While talking to the Express Tribune, former finance minister Miftah Ismail expressed deep sorrow over the demise of Dr Akhtar. “It is deeply saddening to hear about Dr Shamshad Akhtar’s passing. She was a great Pakistani who made her name both nationally and internationally. May she rest in peace. Ameen,” he said.

“Dr Shamshad Akhtar was more than an accomplished economist. She was a trailblazer who opened doors for women in the financial industry. Her leadership, integrity, and resilience made her a role model for generations aspiring to serve in economic and public policy roles.,” commented Arif Habib Limited Head of Research Sana Tawfik.

I always admired her. As a woman in a traditionally male-dominated financial world, Dr Akhtar proved that competence and courage can redefine leadership. She inspired countless young women to believe that they, too, belong at the highest decision-making tables, Tawfik added.

PSX CEO Farrukh H. Sabzwari also expressed sorrow and paid rich tribute to Dr Shamshad Akhtar. When contacted, he said, “It is with profound sorrow that we mourn the passing of Dr Shamshad Akhtar, Chairperson of the Pakistan Stock Exchange. Her visionary leadership, dedication, and unwavering commitment to strengthening Pakistan’s financial landscape have left an indelible mark on our institution and the country.”

“This is a great loss not only for PSX but for Pakistan as a whole. We extend our deepest condolences to her family and loved ones, and we honor her legacy with gratitude and respect,” he added.

Dr Akhtar’s legacy extends far beyond the offices she held. Her passing marks the end of an era for Pakistan’s economic leadership, with colleagues and policymakers remembering her as a steady hand during crises and a respected voice on the global financial stage.





Source link

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Business

FTSE 100 soars as Middle East peace hopes grow

Published

on

FTSE 100 soars as Middle East peace hopes grow



European stocks rallied on Wednesday as comments from both sides of the Middle East war gave some conviction for a near-term end to hostilities.

“The market appears increasingly optimistic that an end to the war in Iran is in the offing as big gains in the US and Asia were matched in Europe,” said AJ Bell investment director Russ Mould.

The FTSE 100 closed up 188.34 points, 1.9%, at 10,364.79. The FTSE 250 ended up 484.48 points, 2.3%, at 21,688.19, and the AIM All-Share advanced 22.13 points, 3.1%, at 739.25.

On Wednesday, US President Donald Trump said that Iran had asked for a ceasefire but that the US would only consider this once the Strait of Hormuz, the vital oil and gas shipping route which Iran has effectively closed for most exports, is clear for shipping.

This came after Mr Trump told reporters on Tuesday the US would end operations in Iran “very soon”, perhaps within “two weeks, maybe three”.

The US president is due to make a televised address later on Wednesday.

Meanwhile, Iranian President Masoud Pezeshkian said the Islamic republic had the “necessary will” to end the war, provided its enemies guaranteed it would not flare up again.

But Israeli Prime Minister Benjamin Netanyahu insisted that Israel would press ahead with its military campaign and that “we will continue to crush the terror regime”.

Brent oil traded lower at 101.83 dollars a barrel on Wednesday afternoon, from 107.38 dollars late on Tuesday.

In European equities on Wednesday, the CAC 40 in Paris closed up 2.1%, while the DAX 40 in Frankfurt rose 2.7%.

Stocks in New York were higher, extending Tuesday’s bumper gains. The Dow Jones Industrial Average was up 0.9%, as was the S&P 500 index, and the Nasdaq Composite advanced 1.3%.

Michael Brown, senior research strategist, at Pepperstone pointed out that amid the “euphoria, exuberance, and relief” which has driven a rebound in risk appetite over the last day or so, the surge in energy prices means that a rise in headline inflation over the next few months is, essentially, “baked in”.

“Added to which, considerably higher energy prices, and continued supply chain disruption, are likely to bring with them substantial growth headwinds, in turn amounting to a notable negative demand shock, which will likely weaken what is already very anaemic economic momentum, most notably in Europe,” he said.

Mr Brown does not think financial markets have “ignored” these risks, but are essentially “parking these worries, to be dealt with on some other day in the future”.

Reflecting these concerns, the Bank of England said the Middle East war had caused “a substantial negative supply shock to the global economy”, increasing risks to the financial system.

The central bank said the fallout will also weigh on economic growth and tighten financial conditions, such as restricted lending by banks.

“Adverse impacts on the global macroeconomy increase the likelihood that multiple vulnerabilities could crystallise at the same time, amplifying their effect on financial stability,” the Bank said in a quarterly update on identifying risks to financial stability.

Bank governor Andrew Bailey sought to dampen expectations of interest rate hikes.

In an interview with Reuters, Mr Bailey responded to market expectations for higher rates by commenting “that is a ​judgment markets have to make but I think they’re getting ahead of themselves”.

Prime Minister Sir Keir Starmer said the UK could weather the economic storm caused by the Iran conflict but acknowledged the crisis will “affect the future of our country” as households faced higher fuel costs now and the prospect of energy bill hikes later this year.

The UK is leading a diplomatic initiative to reopen the Strait of Hormuz, but restoring the flow of global trade will not be easy, Sir Keir admitted.

Foreign Secretary Yvette Cooper will host an international meeting on Thursday to “assess all viable diplomatic and political measures” to reopen the strait, after 35 countries signed up to a statement expressing willingness to contribute to efforts to ensure safe passage for shipping.

The yield on the US 10-year Treasury narrowed to 4.31% on Wednesday from 4.33% on Tuesday. The yield on the US 30-year Treasury ebbed to 4.89% from 4.91%.

The pound rose to 1.3324 dollars on Wednesday afternoon from 1.3205 dollars at the equities close on Tuesday. Against the euro, sterling firmed to 1.1476 euro from 1.1463 euro.

The euro stood higher against the greenback at 1.1608 dollars from 1.1523 dollars. Against the yen, the dollar was trading lower at 158.66 yen compared to 159.02 yen.

On the FTSE 100, the risk-on mood saw gains for banks Lloyds, up 5.8%, NatWest, up 5.4%, and Barclays, up 5.1%.

British Airways owner, International Consolidated Airlines, flew 5.7% higher, budget airlines easyJet and Wizz Air soared 5.0% and 6.2% respectively.

But housebuilder Berkeley Group plunged 9.7% as its decision to halt land buying amid the uncertainty sparked by the Iran war sparked significant profit downgrades.

In an unscheduled trading update, the Surrey-based housebuilder said its fears, expressed in a recent trading statement, that the economic consequences of the conflict in the Middle East could reduce confidence in a near-term market recovery has “now become a reality”.

The builder said it is reducing work in progress investment to match current sales levels and will not acquire new land.

Berkeley anticipates delivering above £1.4 billion of pre-tax profit, over financial 2027 to 2030, which analysts at RBC Capital Markets said was 29% below Visible Alpha consensus of £1.98 billion.

Mr Mould said Berkeley has a “long-standing reputation for being adroit at calling the ups and downs of the property market”.

“In that context, the moves the company has announced today will make others sit up and take notice,” he said.

Rightmove fell 1.4% as it said it will “defend vigorously” a proposed class action claim filed against it, as estate agents accuse the firm of charging excessive fees.

The London-based online property portal confirmed it is aware of reports that an application to commence collective proceedings has been filed with the UK’s Competition Appeal Tribunal.

On the FTSE 250, Trustpilot climbed 7.3% as Panmure Liberum upgraded to “buy” from “hold”, while Raspberry Pi extended Tuesday’s bumper gains with a further 13% rise.

Gold traded at 4,781.92 dollars an ounce on Wednesday, up from 4,613.15 dollars at the same time on Tuesday.

The biggest risers on the FTSE 100 were Babcock International, up 110.0p at 1,268.0p, Rolls Royce, up 75.0p at 1,207.0p, 3i Group, up 146.0p at 2,584.0p, Endeavour Mining, up 260.0p at 4,720.0p and Fresnillo, up 192.0p at 4,720.0p.

The biggest fallers on the FTSE 100 were Berkeley Group, down 332.0p at 3,104.0p, BP, down 30.3p at 576.0p, Shell, down 139.5p at 3,443.5p, Rightmove, down 6.0p at 422.9p and British American Tobacco, down 58.0p at 4,313.0p.

Thursday’s global economic calendar has trade figures in the US and Canada, and US weekly jobless claims.

Thursday’s domestic corporate calendar has half year results from Baillie Gifford Japan Trust.

– Contributed by Alliance News



Source link

Continue Reading

Business

Factory input price inflation jumps by most since 1992 due to Iran war – survey

Published

on

Factory input price inflation jumps by most since 1992 due to Iran war – survey



Britain’s manufacturing sector has seen the biggest monthly jump in input prices for more than 30 years as the Iran war wreaks havoc on supply chains, according to a survey.

The S&P Global UK manufacturing purchasing managers’ index (PMI) survey, watched closely by economists, showed that the input price inflation index jumped by 15 points between February and March – the biggest rise since the UK withdrew from the European Exchange Mechanism (ERM) on so-called Black Wednesday in 1992.

The report also showed that delivery delays worsened due to the Middle East conflict as ships have been forced to re-route around the blocked Strait of Hormuz, which is a key shipping route.

Manufacturing production also contracted for the first time in six months in March, according to the survey.

Overall activity slipped back, with the PMI recording a reading of 51 in March, down from 51.7 in February and lower than the 51.4 flash estimate earlier this month.

Any reading above 50 indicates that activity is growing while any score below means it is contracting.

Rob Dobson, director at S&P Global Market Intelligence, said: “UK manufacturing output contracted for the first time in six months in March, as the war in the Middle East and ongoing concerns about domestic economic policy led to a scaling back of production.

“The impact of the war also caused noticeable shifts in the cost and supply chain backdrops.

“Delivery times lengthened to the greatest extent since mid-2022, while the acceleration in input price inflation was the steepest since the aftermath of the UK’s withdrawal from the ERM in 1992.”

The survey found that almost half of companies (49%) reported an increase in purchase prices, while only 2% saw a decrease last month.

It said the Iran conflict had a “marked” impact on supply chains, with average vendor delivery times growing by the most in more than four-and-a-half years.

The survey also showed an impact on jobs in the sector, with the latest round of cuts the steepest since last September.

But there was a chink of light with new orders remaining resilient as they rose for the fourth successive month in March, albeit at a slower pace than in February.

Mr Dobson said: “This suggests that the drop in production is currently more of a supply issue than one caused by an outright downturn in demand, though it’s hard to see how demand can prove resilient in the face of current high energy prices and economic uncertainty unless there’s a swift resolution to the war in the Middle East.”

Expert Mike Thornton, head of industrials at RSM UK, said: “The control of the Strait of Hormuz is one of the biggest commercial issues for manufacturers and issues will pile up the longer access is blocked.

“The increase in energy costs will be a persistent headwind, but worries relating to supply chain disruption are growing.”

A separate report from banking giant Barclays on Wednesday showed firms are already taking action to offset trading and cost pressures from the Iran war, with 43% seeing shipping and logistics costs hitting their profitability.

The lender’s business prosperity index revealed almost four in 10 (37%) are reducing their energy use or boosting supply chain efficiency, while nearly a third (32%) have changed their pricing to offset rising costs.

More than a third (34%) of the 500 business leaders polled for the survey are planning to pass on higher costs to consumers.

And over a quarter (29%) are cutting non-essential spending or wider operational costs, according to the report.



Source link

Continue Reading

Business

FDA approves Eli Lilly’s GLP-1 pill, opening the next phase of the weight loss drug market

Published

on

FDA approves Eli Lilly’s GLP-1 pill, opening the next phase of the weight loss drug market


The U.S. Food and Drug Administration approved Eli Lilly‘s GLP-1 pill, the company said, a major milestone for the Indianapolis-based drugmaker and one that will test the market for new weight-loss medications.

Lilly said the once-daily pill, Foundayo, will start shipping from direct-to-consumer platform LillyDirect on Monday and will be available at pharmacies and on telehealth platforms “shortly after.” People with insurance coverage could pay $25 a month with a coupon from Lilly, while people paying out of pocket could pay between $149 and $349, depending on the dose.

The approval comes just a few months after Lilly submitted the drug to the FDA as part of a program that grants speedy reviews for drugs that are considered national priority interests. That means Lilly will introduce its Foundayo only about three months behind Novo Nordisk’s Wegovy pill, setting the stage for the next battle between the rival drugmakers in the next frontier for GLP-1 drugs.

“It’s a big moment,” Eli Lilly CEO Dave Ricks said in an interview with CNBC. “We’ve obviously been working in this category of medicines for a while with the first GLP-1 medication 20 years ago and improving ever since. Here is an option that’s not more effective … but it’s more accessible, it’s easier to fit into your daily routine.”

Lilly licensed the molecule, orforglipron, from Japanese drugmaker Chugai in 2018, paying just $50 million upfront for global rights to the drug. But there are still questions about how big the drug will become. It doesn’t produce as much weight loss as Lilly’s best-selling shot Zepbound. Millions of people are already used to the routine of injecting themselves once a week.

Eli Lilly Foundayo GLP-1 weight loss pill.

Courtesy: Eli Lilly

Analysts estimate Foundayo sales will reach $14.79 billion by 2030, according to FactSet. That compares to expectations of $24.68 billion for the weight-loss drug Zepbound and $44.87 billion for Mounjaro, which is marketed for diabetes in the U.S. and obesity and diabetes in the rest of the world.

Ricks said shots haven’t been as big of a barrier to uptake as Lilly once thought they would be. He still sees Foundayo as an attractive option for people who would rather take a pill or who are searching for a lower price than the injectables.

He sees it playing a role in maintenance, for people who achieve their goal weight with a shot and want to keep the weight off. And he sees Foundayo as a way to “reach the planet” without manufacturing constraints or cold-chain requirements that come with Zepbound.

Foundayo is a small molecule whereas Zepbound and Wegovy are peptides, which require more intensive manufacturing processes, a barrier Ricks thinks will hinder generic versions of Wegovy that have recently launched in some other countries like India.

“[Foundayo] does allow for scalability, and that will allow us to launch this globally on the first instance,” Ricks said. “So today, you can get the oral [Wegovy] in the U.S., but you really can’t get it elsewhere. This will be marketed around the world. As soon as we have regulatory approvals, we essentially have as much scale as we need to supply the world with an oral GLP-1 inhibitor.”

Lilly expects approval for Foundayo in more than 40 countries over the next year. The company since 2020 has invested more than $55 billion in manufacturing, which includes opening new sites and expanding existing plants to produce the pill.

In the U.S., Lilly will compete with Novo’s newly launched Wegovy pill. Early demand for that pill has been stronger than expected, with Novo reporting more than 600,000 prescriptions in March.

Novo CEO Mike Doustdar told CNBC in February that one of the earliest takeaways from the launch is that the pill appears to be expanding the obesity treatment market, drawing in new patients rather than converting existing ones from injections. Ricks agreed with that assessment and said Lilly doesn’t care whether people take Foundayo or Zepbound.

“We want people to be on the medicine that meets their health goals,” Ricks said. “If it has Lilly on the box, that’s the goal we have.”

Novo plans to argue that the Wegovy pill is more effective than Foundayo. The Wegovy pill showed around 16.6% weight loss on average in a late-stage trial, while Lilly’s oral drug caused roughly 12.4% on average in a separate study, when analyzing patients who stayed on treatment. Lilly’s Zepbound has consistently shown it can help people lose more than 20% of their body weight.

Meanwhile, Lilly plans to tout the fact that Foundayo can be taken any time without any restrictions, while the Wegovy pill needs to be taken first thing in the morning on an empty stomach with only a few ounces of water.

Where the two drugs are the same is the starting price. The lowest doses of both drugs will cost $149 for cash-paying customers thanks to an agreement the companies struck with the Trump administration last fall. And price is the most important factor for patients, said Dr. Nidhi Kansal, an obesity medicine doctor at Northwestern Medicine.

“Unfortunately, price is what is driving the decision making between clinicians and patients for these drugs because they’re all excellent drugs and we have lots of options now, but it’s still a financial decision at the end of the day,” Kansal said.

The lower price point and the approachability of a pill versus a shot opens up the market to casually interested patients, said BMO Capital Markets analyst Evan David Seigerman. Seniors on Medicare will be able to access Foundayo and other GLP-1 obesity medicines for $50 a month starting this summer as part of Lilly and Novo’s deals with the Trump administration. Ricks expects a “pretty robust” response to the program, which Lilly built into its financial guidance for the year.

Analysts say a successful launch of Foundayo is key to Lilly’s stock recovering from recent weakness. The company’s shares have fallen about 14% this year after a meteoric rise that briefly made Lilly the first trillion dollar market cap health-care company. Sales are a lagging indicator, so analysts will be tracking prescriptions to monitor uptake of the pill, said Cantor Fitzgerald analyst Carter Gould.

“If scripts are going in the right direction, and you’re seeing the continued gains, my guess is people will look through any sort of choppiness around [the first or second quarter],” Gould said.

Another factor for Lilly’s performance this year is a forthcoming readout for its more potent obesity shot, retatrutide. The company has already shared some late-stage data on that drug, but the most important trial is one studying the treatment specifically for weight loss. If retatrutide lives up to its expectations, Lilly would be on its way to creating a portfolio of obesity medicines.

“The future will be more choices, and that’s a great thing,” Ricks said. “And we hope Lilly is the one presenting those choices.”

Choose CNBC as your preferred source on Google and never miss a moment from the most trusted name in business news.



Source link

Continue Reading

Trending